更多精彩内容，敬请关注钛媒体微信公众号（ID：taimeiti），或下载钛媒体App
新规引入「生理指标」与「背景核查」辅助认定方式：
。关于这个话题，搜狗输入法AI Agent模式深度体验：输入框变身万能助手提供了深入分析
The study titled "Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8)" was pulled from BMJ on March 31, 2026. Shortly after its release in October 2025, multiple issues were identified concerning the study's methodology, execution, and data presentation. The journal's editors published a notice of concern in November 2025, citing potential deviations from standard research protocols.
Ok, you sit down to get cracking on compliance. What do you do next?